Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bristol Hopeful Of Quick Reply To Eliquis CRL; Points To Sales Growth Aside From Recent Patent Expiries

This article was originally published in The Pink Sheet Daily

Executive Summary

With a patent cliff that just turned worse with the patent expiration of Plavix, Bristol-Myers Squibb talked about how it long has planned for these events and says the Amylin transaction positions it to offer a full spectrum of diabetes drugs across three different mechanisms of action.

You may also be interested in...



Eliquis Superiority Claim May Be At Stake In “Complete Response” Letter

FDA could have concerns about the reported data from the ARISTOTLE trial, either from the bleeding comparisons or the dosing in the warfarin control arm. Missing data is another possible issue, as in the recent “complete response” letter for J&J/Bayer’s Xarelto.

Bristol’s New Anti-PD-1 Immunotherapy An ASCO High Point

Bristol-Myers Squibb’s “anti-PD-1,” an antibody that gets between immune system T-cells out to destroy cancer cells and a cancer defense mechanism that would tie them up, caught the fancy of attendees at the American Society of Clinical Oncology annual meeting in Chicago with Phase I data indicating the drug could be safer and more effective than Bristol’s breakthrough immunotherapeutic for melanoma, Yervoy.

Plavix Takes A Final Bow, But Will It Go Gracefully?

Generic versions of Bristol-Myers Squibb/Sanofi’s blockbuster clot-buster clopidogrel launched in the U.S. May 17, but the companies are helping some patients continue on the brand by covering the high out-of-pocket costs. Following Pfizer’s success retaining share of Lipitor, industry is paying close attention to brand retention programs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074433

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel